Fms-like tyrosine kinase 3 positive acute myeloid leukemia is a challenging form of blood cancer that occurs when specific mutations cause bone marrow cells to grow uncontrollably, carrying a higher risk of relapse and requiring specialized treatment approaches.
Understanding the Prognosis
Learning about the expected course of FLT3-positive acute myeloid leukemia (often shortened to FLT3-positive AML) can be difficult for patients and their families. This particular form of leukemia is known to have a more challenging outlook compared to other types of AML. The presence of FLT3 mutations, especially the internal tandem duplication type (FLT3-ITD), is associated with a higher likelihood that the disease will return after treatment.[1]
Research shows that patients with FLT3-positive AML face specific challenges in their treatment journey. While these patients can often achieve complete remission—meaning that signs of cancer disappear after initial treatment—the disease tends to come back more frequently than in other types of AML. Studies have documented that the FLT3-ITD mutation has no negative impact on achieving that first complete remission, but it does increase the risk for relapse, decrease disease-free survival, and shorten overall survival.[3]
The survival statistics vary depending on treatment approaches. In one major clinical trial comparing different treatment strategies, patients who received a targeted medication called midostaurin along with chemotherapy had a median overall survival of 74.7 months, compared to 25.6 months for those who received chemotherapy with a placebo. This represents a 22% lower risk of death for patients receiving the targeted therapy.[3]
Research has also found that patients with FLT3-positive AML who have high levels of a protein called CHK1 tend to have lower overall survival rates and disease-free survival rates compared to those with lower levels of this protein.[4] This finding highlights how multiple biological factors work together to influence the course of the disease.
How the Disease Naturally Progresses
Understanding what happens when FLT3-positive AML develops without treatment helps explain why prompt medical care is so important. The FLT3 gene normally produces a protein that acts as a receptor on the surface of blood-forming cells. This receptor plays an important role in helping these cells grow and develop properly. When mutations occur in the FLT3 gene, the resulting abnormal protein becomes constantly active, even when it shouldn’t be.[1]
This constant activation sets off a cascade of problems inside the cells. The mutated FLT3 protein triggers downstream signaling pathways, particularly those involving proteins called STAT5 and PIM, as well as pathways known as PI3K-AKT. These activated pathways cause the leukemia cells to multiply rapidly and avoid the normal cell death processes that would usually eliminate damaged or abnormal cells.[4]
The uncontrolled growth of these abnormal cells in the bone marrow creates serious problems throughout the body. As leukemia cells accumulate, they crowd out the normal blood-forming cells that would typically produce healthy red blood cells, white blood cells, and platelets. This leads to a shortage of these essential blood components. Patients may become anemic from too few red blood cells, vulnerable to infections from insufficient normal white blood cells, and prone to bleeding from inadequate platelets.
The FLT3-ITD mutation also creates unusual stress inside the cells, particularly affecting DNA replication. This DNA replication stress is one of the ways the mutation drives the disease forward, constantly pushing cells to divide even when conditions aren’t appropriate for healthy cell division.[4] Without treatment to interrupt these processes, the disease progresses rapidly, with increasing numbers of abnormal cells and worsening symptoms.
Possible Complications That May Arise
Patients with FLT3-positive AML face several potential complications beyond the primary disease itself. One of the most significant challenges is the development of resistance to treatments. Even when targeted therapies initially work well to control the leukemia, cancer cells can develop ways to bypass or overcome these treatments. This phenomenon, known as primary or secondary resistance, remains a major obstacle in the long-term management of FLT3-positive AML.[5]
The disease carries a particularly high risk of relapse, meaning the cancer returns after a period of remission. Because FLT3 mutations are associated with aggressive disease behavior, the cancer can come back even after treatments that initially appeared successful. This tendency toward relapse is one reason why doctors often recommend more intensive treatment approaches or bone marrow transplantation for patients with FLT3-positive AML.[1]
Some patients may have both FLT3-ITD and another type of FLT3 mutation called TKD at the same time. This combination is rare, occurring in a small percentage of cases, but when it does happen, it carries worse clinical outcomes than having a single mutation type.[3] The presence of multiple mutations makes the disease more difficult to control with standard treatment approaches.
The intensive treatments required for FLT3-positive AML can themselves lead to complications. Chemotherapy affects not only cancer cells but also rapidly dividing normal cells throughout the body. Patients may experience severe infections when their white blood cell counts drop, require blood transfusions when red blood cells or platelets become too low, and face other side effects related to their treatment regimens. Bone marrow transplantation, when recommended, carries its own set of risks including graft-versus-host disease, where transplanted cells attack the patient’s own tissues.
Research has shown that the abnormal FLT3 protein affects other cellular processes beyond just cell growth. It can recruit other proteins and change how genes are regulated through a process called epigenetic modification. These changes can enhance the expression of other proteins that help the cancer cells survive, creating a complex web of biological problems that contribute to disease progression and treatment resistance.[4]
Effects on Daily Life
Living with FLT3-positive AML affects virtually every aspect of a person’s daily routine. The disease itself causes profound fatigue that goes beyond normal tiredness. This exhaustion stems from anemia and the body’s overall struggle to function properly with disrupted blood cell production. Simple activities that were once routine—climbing stairs, preparing meals, or even getting dressed—can become exhausting tasks that require careful planning and frequent rest periods.
The emotional impact of a FLT3-positive AML diagnosis can be overwhelming. Learning that you have an aggressive form of leukemia with a higher risk of relapse naturally causes anxiety, fear, and uncertainty about the future. Many patients describe feeling like their lives have been put on hold, with plans and dreams suddenly seeming uncertain. Depression is common, particularly during the intensive treatment phases when patients feel physically ill and isolated from their normal activities and relationships.
Treatment for FLT3-positive AML often requires extended hospital stays, particularly during the initial intensive chemotherapy phases. These hospitalizations separate patients from their families, homes, and familiar routines. Even when patients are at home, they must often limit contact with others to reduce infection risk, especially when their immune systems are compromised by treatment. This isolation can feel particularly difficult during holidays, special occasions, or simply when craving normal social interaction.
Work and financial concerns add another layer of stress. Many patients must take extended medical leave or stop working entirely during treatment. The physical demands of treatment, frequent medical appointments, and unpredictable energy levels make it difficult or impossible to maintain regular employment. Even for those who want to work, the intensive nature of AML treatment often makes it medically inadvisable. Financial worries about medical bills, lost income, and ongoing living expenses can compound the stress of dealing with the disease itself.
Hobbies and activities that once brought joy may need to be modified or temporarily abandoned. Physical activities may be limited by fatigue, low blood counts, or the need to avoid injury when platelet counts are low. Activities that involve exposure to crowds or potential sources of infection may be off-limits when the immune system is compromised. Creative or intellectual pursuits may be affected by concentration difficulties caused by the disease, medications, or the overall stress of the situation.
Family roles and relationships often shift significantly. A parent who was once the primary caregiver may now need care from their spouse or even their older children. The patient may feel guilty about being unable to fulfill their usual responsibilities or about the burden their illness places on loved ones. Conversely, family members take on new caregiving roles, which can be both emotionally rewarding and physically exhausting.
Supporting Family Members Through Clinical Trials
Family members play a crucial role when a loved one with FLT3-positive AML considers participating in clinical trials. Clinical trials are research studies that test new treatments or new combinations of existing treatments. For patients with FLT3-positive AML, clinical trials may offer access to promising new targeted therapies that aren’t yet widely available.[5]
Understanding what clinical trials involve is the first step in supporting your loved one. These studies test new FLT3 inhibitors—medications designed to block the abnormal protein produced by the mutated gene. Second-generation inhibitors like quizartinib, crenolanib, and gilteritinib are more selective and potent than earlier versions, specifically targeting the FLT3 protein while affecting fewer other proteins in the body.[3] Trials may also test combinations of FLT3 inhibitors with other types of cancer treatments.
Families can help by researching available trials and organizing information about each option. This includes understanding what phase of trial is being offered. Early phase trials test safety and dosing, while later phase trials compare new treatments to standard treatments. Each has different purposes, risks, and potential benefits. Having this information organized makes it easier for the patient and their medical team to make informed decisions.
Attending medical appointments with your loved one provides valuable support during discussions about clinical trials. Having a second person present helps ensure important information isn’t missed and provides emotional support during what can be overwhelming conversations. Family members can take notes, ask clarifying questions, and help the patient remember details later when making decisions at home.
Practical support is essential when someone participates in a clinical trial. Trials often require more frequent visits to the treatment center than standard care, including regular blood tests, imaging studies, and check-ups to monitor how the treatment is working and watch for side effects. Family members can help by providing transportation to appointments, attending visits when possible, and keeping track of the complex schedule of required visits and tests.
Emotional support becomes even more important during clinical trial participation. Your loved one may feel anxious about trying an unproven treatment, worried about whether they made the right choice, or frustrated if the trial doesn’t produce the hoped-for results. Family members can listen without judgment, help maintain perspective, and remind the patient that participating in research contributes to advancing treatment for future patients, regardless of individual outcomes.
Helping manage medications and side effects is another important role families can fill. Clinical trials may involve complex medication schedules, and some FLT3 inhibitors can cause side effects that need careful monitoring. Family members can help ensure medications are taken as prescribed, watch for concerning symptoms, and communicate with the medical team about any problems that arise.
Communication with the clinical trial team should be open and ongoing. Families should feel comfortable asking questions about any aspect of the trial, from understanding consent forms to clarifying what will happen if the treatment doesn’t work or causes problems. The team wants participants and their families to be well-informed and comfortable throughout the process.
